Results 191 to 200 of about 138,725 (257)

Efficacy and Tolerability of Brevilin-A, a Natural JAK Inhibitor, in Pediatric Alopecia Areata: A Case Series. [PDF]

Clin Cosmet Investig Dermatol
Matteini E, Diluvio L, Lambiase S, Cioni A, Gaeta Shumak R, Costanza G, Lanna C, Caldarola G, Bianchi L, Campione E.   +9 more
europepmc   +1 more source

JAK Inhibitors for Granuloma Annulare: Hope for Refractory Cases? [PDF]

Defne Özkoca, Seçil Vural
openalex   +1 more source

Complete response to mTOR inhibitor following JAKi failure in severe pulmonary sarcoidosis: Authors’ reply

Pulmonology
Raphaël Hindré, Valérie Besnard, Fatma Kort, Hilario Nunes, Dominique Valeyre*, Florence Jeny*   +5 more
doaj   +1 more source

Have we hit the JAK-pot? Success of selective JAK 1 inhibitor following failure of pan-JAK inhibitor in refractory pediatric ulcerative colitis. [PDF]

JPGN Rep
Black JA, Pasternak B.
europepmc   +1 more source

Successful treatment of refractory amyopathic dermatomyositis with upadacitinib in prior JAK inhibitor failure. [PDF]

JAAD Case Rep
Sohn A, Bouché N, Lewitt GM, Song EJ.
europepmc   +1 more source

Author Correction: Exploratory study on the efficacy of topical pan-JAK inhibitor in ocular and skin GVHD in a sclerodermatous GVHD mouse model. [PDF]

Sci Rep
Sato S, Ogawa Y, Asai K, Shimizu E, Shimizu S, Taniguchi H, Okazaki T, Shimmura S, Negishi K, Hirayama M.   +9 more
europepmc   +1 more source

Successful treatment of the dupilumab-induced psoriatic dermatitis/arthritis and atopic dermatitis with a JAK inhibitor: A case report and literature review. [PDF]

J Allergy Clin Immunol Glob
Tsunoda M, Adachi T, Nakajima Y, Yatomi Y, Shimizu T, Nakasute K.   +5 more
europepmc   +1 more source

Cutaneous T-cell lymphoma in a JAK inhibitor patient: A case report. [PDF]

SAGE Open Med Case Rep
Mo S, Friedmann D.
europepmc   +1 more source

Multicentre, 26-week, open-label phase 2 trial of the JAK inhibitor filgotinib in Behçet's disease, idiopathic inflammatory myopathies and IgG4-related disease: DRIMID study protocol. [PDF]

BMJ Open
Geertsema-Hoeve BC, van Laar JAM, Raaphorst J, Tas SW, Welsing PMJ, Goekoop RJ, Checa CM, Thurlings RM, Rekers NH, Present E, van Laar JM.   +10 more
europepmc   +1 more source

Treatment of Moderate-to-severe Atopic Dermatitis with Upadacitinib: Results from an Interim Analysis of the TREATgermany Registry

Acta Dermato-Venereologica
Barbara Kind, Luise Heinrich, Thomas Werfel, Jochen Schmitt, Stephan Weidinger   +4 more
doaj   +1 more source